A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance

Recent performance snapshot

EyePoint (EYPT) has drawn attention after mixed recent returns, with the share price up about 7% over the past month but showing a decline over the past 3 months and year to date.

At a last close of US$13.90 and a market value of about US$1.12b, investors are weighing this performance against the company’s focus on retinal disease treatments and its developing product pipeline.

See our latest analysis for EyePoint.

That mix of a 7.42% 30 day share price return alongside a 16.57% 90 day decline suggests momentum has cooled recently. At the same time, the 1 year total shareholder return of 123.83% and 3 year total shareholder return of about 4.5x still point to a strong longer term payoff for investors who stayed the course.

If you are comparing EyePoint with other growth stories in healthcare, it can help to scan a wider field of retinal and biotech peers through a focused healthcare AI stock list such as 36 healthcare AI stocks.

With EyePoint trading at US$13.90, an intrinsic value estimate signaling a large discount and analyst targets far above the current price, you have to ask if this is a genuine opportunity or if markets already expect strong future growth.

Most Popular Narrative: 62.5% Undervalued

With EyePoint last closing at $13.90 and the most followed narrative pointing to a fair value of about $37.08, the gap between price and modeled value is wide and centers on how DURAVYU could reshape the business.

Analysts have raised their average price target for EyePoint to approximately $37 per share, up from about $36. They attribute this change to updated assumptions following the Q4 results, including the integration of the Phase 3 diabetic macular edema program and revised expectations for the Duravyu franchise.

Read the complete narrative.

Want to see what underpins that fair value jump? The narrative focuses on rapid revenue expansion, a sharp margin reset, and a premium future earnings multiple. Curious which assumptions carry the most weight in that model and how sensitive the outcome is if they shift even slightly?

Based on this narrative, EyePoint screens as heavily undervalued, with a fair value of $37.08 calculated using a 6.98% discount rate that reflects the implied risk in those future cash flow estimates.

Result: Fair Value of $37.08 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that upside story hinges on DURAVYU clearing key clinical and regulatory hurdles, while EyePoint carries ongoing net losses and relies heavily on a single lead asset.

Find out about the key risks to this EyePoint narrative.

Another angle on valuation

On the flip side of that big discount to fair value, EyePoint trades on a P/S of about 37x, compared with roughly 4x for the wider US pharmaceuticals group and around 0.8x for peers. The fair ratio model also points to 0x, so how comfortable are you paying such a premium today?

For a closer look at what the numbers imply for valuation risk, it is worth reviewing the detailed breakdown behind that sales multiple, including how it stacks up against sector peers and what would need to change for the market to move toward the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

All this mixed sentiment around valuation and pipeline risk sets the scene, but your own judgment should come from the data itself. Act while the details are fresh, weigh both the concerns and the potential upside, and see the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If you leave it here, you only see one angle. Broaden your opportunity set and use the screener tools to spot ideas that match your style and risk comfort.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com